$360B Women's Health Ghost Market Report

Amboy Street is excited to announce its latest investment in Millie - a midwifery-led, hybrid maternity clinic providing in-person and virtual care.

We analyzed our annual Top 10 Deals blog series from 2021 - 2024 and identified the most active acquirer profiles in women’s health and sexual health.

For our last deal in the Top 10 Deals of 2024 series, we explore a major acquisition in women’s health biopharma - a deal that advances innovation in the treatment of ovarian cancer, one of the deadliest forms of the disease.

Amboy Street Ventures is excited to announce its latest investment in Gesynta Pharma - developing a novel non-hormonal drug candidate for the treatment of endometriosis.

This blog highlights one of the largest growth capital investments made in Femtech this year. Led by General Atlantic, the deal highlights a growing interest in the women’s health sector from prominent generalist firms.

This week we highlight a second acquisition by the active women’s health acquirer, Hologic, in a large market segment of women’s health: breast cancer.

This week we explore one of a growing number of consolidation plays in the IVF space, IVI RMA’s acquisition of Boston IVF and TRIO. This trend suggests there is value in 4-wall IVF clinics, reflecting an interesting area of investment.

This blog assesses a recent women’s health deal that expands treatment options for uterine fibroids and abnormal uterine bleeding. These indications are infrequently discussed and therefore unfamiliar to many, yet impact a significant number of women, especially those in perimenopause.

This week we delve into a major acquisition touching multiple areas of women’s health. A deal like this demonstrates a strong appetite for women’s health innovation, across indications, as acquirers recognize the financial viability in meeting these needs.